We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-12.09%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$139M
AUM Growth
-$32.4M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
7
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 92.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GKOS icon
1
Glaukos
GKOS
$9.29B
$52.9M 38.17%
3,136,232
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$44.4M 32.04%
1,092,152
OCUL icon
3
Ocular Therapeutix
OCUL
$1.83B
$21.4M 15.45%
2,215,384
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$7.82M 5.65%
407,416
BITI
5
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$7.09M 5.12%
268,672
AKAO
6
DELISTED
Achaogen Inc
AKAO
$3.54M 2.55%
1,281,152
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$1.42M 1.02%
1,048,601

Similar funds

Versant Venture Management's Q1 2016 Portfolio in Review

As of Q1 2016, Versant Venture Management held 7 positions worth $139M, down 19% from $171M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2016: portfolio turnover was 0%. Versant Venture Management opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

  • Versant Venture Management's ten largest holdings make up 100% of its $139M portfolio in Q1 2016.
  • Versant Venture Management opened 0 new positions and closed 0 in Q1 2016.
  • Versant Venture Management's portfolio value fell 19% quarter-over-quarter to $139M.

Based on Versant Venture Management's 13F filing for Q1 2016, filed 25 Apr 2016.